Core Viewpoint - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological (300871.SZ), has approved an investment of 170 million yuan for the upgrade of its veterinary raw material drug production line through a green equipment technology transformation project [1] Investment Project Summary - The project will be executed in two phases, focusing on upgrading the existing technology and equipment of the veterinary raw material drug production line [1] - The funding for the project will be sourced from the company's own funds [1] Technical Enhancements - The project aims to enhance technology and optimize the composition of production line equipment, introducing new and updated high-efficiency, energy-saving, and highly automated equipment [1] - The upgrade will increase the production capacity of existing raw material drug varieties and add new production lines for fermentation products [1] - The project will also focus on reducing and resourcefully utilizing fermentation waste, as well as upgrading energy-saving measures in systems such as energy storage, air compression, stirring, and wastewater treatment [1] Production Efficiency - The optimization of the production line equipment composition will ensure that the capacity of upstream and downstream equipment is matched, maximizing production line capacity while reducing energy consumption and lowering labor and maintenance costs [1]

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of the year, indicating strong operational performance and market demand [1] Financial Performance - The company achieved operating revenue of 822.20 million yuan, an increase of 88.45% compared to the same period last year [1] - The net profit attributable to shareholders reached 117.18 million yuan, reflecting a substantial growth of 325.88% year-on-year [1] Segment Performance - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1] - Sales revenue from veterinary raw materials surged by 199.01% compared to the previous year, with a gross margin improvement of 27.14% [1] Financial Impact - The redemption of convertible bonds led to a reduction in interest expenses by 11.31 million yuan, which had a certain impact on net profit [1] - The company declared a cash dividend of 1.00 yuan per 10 shares to all shareholders [1]

Group 1 - The company, Huibei Huisheng Biological Technology Co., Ltd., a wholly-owned subsidiary of Huisheng Biological, plans to invest 170 million yuan in a green equipment technological transformation project for veterinary raw materials [2] - The project will upgrade and transform the existing technology and equipment of the company's veterinary raw material production line in two phases [2] - In the semi-annual report for 2025, the company reported a net profit attributable to shareholders of 117 million yuan, marking a turnaround from losses in the previous year [2] Group 2 - The company intends to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders [2]

Group 1 - The company, Huisheng Biological, announced the convening of its 23rd meeting of the third board of directors on August 5, 2025, to discuss the appointment of a rotating general manager [2] - For the year 2024, the revenue composition of Huisheng Biological is as follows: veterinary raw materials and preparations account for 93.02%, while other segments account for 6.98% [2]

Group 1 - The company announced the implementation of a rotating general manager system, with Mr. Han Jie continuing in this role as approved by the board's nomination committee [2] - For the year 2024, the company's revenue composition is as follows: veterinary raw materials and formulations account for 93.02%, while other segments account for 6.98% [2]

智通财经APP讯，回盛生物(300871.SZ)公告，公司董事会、监事会审议通过了《关于投资建设兽用原料 药绿色设备技改项目的议案》，同意全资子公司湖北回盛生物科技有限公司投资建设兽用原料药绿色设 备技改项目。项目投资金额预计1.7亿元，分两期对公司现有兽用原料药生产线技术及设备进行升级改 造。 公告称，通过分两期系统性改造现有生产线，引入高效节能与自动化装备，实现兽用原料药产品产能的 提升，拓展发酵类产品管线，优化产品结构。 ...

格隆汇8月5日｜回盛生物公告，2025年上半年营业收入8.22亿元，同比增长88.45%；净利润1.17亿元， 同比增长325.88%。公司拟向全体股东每10股派发现金红利1元(含税)。 ...

Group 1 - The company, Huisheng Biological, announced the approval of an investment project for the construction of green equipment for veterinary raw materials [1] - The total investment for the project is estimated at 170 million yuan, which will be executed in two phases to upgrade the existing production line technology and equipment [1] - The project aims to systematically transform the current production line by introducing efficient, energy-saving, and automated equipment to enhance the production capacity of veterinary raw materials and optimize the product structure [1]

Group 1 - The core viewpoint of the article highlights the significant growth in the financial performance of 回盛生物, with a reported revenue of approximately 822 million yuan for the first half of 2025, representing an increase of 88.45% year-on-year [1] - The net profit attributable to shareholders for the same period is approximately 117 million yuan, contrasting with a net loss of about 51.88 million yuan in the same period of 2024 [1] - The basic earnings per share for the first half of 2025 is reported at 0.6622 yuan, compared to a loss of 0.3127 yuan per share in the previous year [1] Group 2 - As of the report's release, the market capitalization of 回盛生物 stands at 5 billion yuan [1]

智通财经APP讯，回盛生物(300871.SZ)发布2025年半年度报告，该公司营业收入为8.22亿元，同比增长 88.45%。归属于上市公司股东的净利润为1.17亿元。归属于上市公司股东的扣除非经常性损益的净利润 为9930.1万元。基本每股收益为0.6622元。此外，拟向全体股东每10股派发现金红利1.00元(含税)。 ...